Found: 15
Select item for more details and to access through your institution.
Functional Glial Activation Mediates Phenotypic Effects of APOEɛ4 and Sex in Alzheimer's Disease.
- Published in:
- Neuroglia, 2024, v. 5, n. 3, p. 323, doi. 10.3390/neuroglia5030022
- By:
- Publication type:
- Article
Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
- Published in:
- International Journal of Neuropsychopharmacology, 2006, v. 9, n. 1, p. 101
- By:
- Publication type:
- Article
Rivastigmine in Dementia Associated with Parkinson's Disease and Alzheimer's Disease: Similarities and Differences.
- Published in:
- Journal of Alzheimer's Disease, 2007, v. 11, n. 4, p. 509, doi. 10.3233/JAD-2007-11412
- By:
- Publication type:
- Article
Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.075908
- By:
- Publication type:
- Article
Butyrylcholinesterase Kalow variant reduces age‐of‐onset of Alzheimer Disease in apolipoprotein ɛ4 carriers.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.075908
- By:
- Publication type:
- Article
Results of the first‐in‐human, randomized, double‐blind, placebo‐controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer's disease
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051871
- By:
- Publication type:
- Article
DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS-MAPTRX, THE FIRST TAU-LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P600, doi. 10.1016/j.jalz.2017.07.242
- By:
- Publication type:
- Article
Butyrylcholinesterase genotype and gender influence Alzheimer’s disease phenotype
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2013, v. 9, n. 2, p. e1, doi. 10.1016/j.jalz.2010.12.005
- By:
- Publication type:
- Article
A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder.
- Published in:
- Psychopharmacology, 2004, v. 171, n. 4, p. 390, doi. 10.1007/s00213-003-1594-8
- By:
- Publication type:
- Article
Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia.
- Published in:
- American Journal of Alzheimer's Disease & Other Dementias, 2010, v. 25, n. 2, p. 142, doi. 10.1177/1533317509333904
- By:
- Publication type:
- Article
Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.
- Published in:
- BMC Neurology, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12883-024-03611-5
- By:
- Publication type:
- Article
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
- Published in:
- Movement Disorders, 2008, v. 23, n. 11, p. 1532, doi. 10.1002/mds.21997
- By:
- Publication type:
- Article
Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
- Published in:
- Journal of Psychopharmacology, 2015, v. 29, n. 5, p. 526, doi. 10.1177/0269881114553252
- By:
- Publication type:
- Article
Restoration of positive mood states in major depression as a potential drug development target.
- Published in:
- 2014
- By:
- Publication type:
- journal article
SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.
- Published in:
- 1998
- By:
- Publication type:
- journal article